Laboratoires Pierre Fabre and XtalPi strike AI drug deal

By Nathan Brooks

Laboratoires Pierre Fabre and XtalPi agreed on November 9, 2026, to a multi-program drug-discovery deal with an upfront payment, multiple milestone payments and downstream economic participation.

The companies said the agreement covers multiple research programs seeking novel small-molecule clinical candidates. Laboratoires Pierre Fabre will select and advance compounds in oncology, with dermatology and rare diseases potentially in scope.

The companies’ announced commercial arrangement follows a three-part structure:

• An upfront payment.
• Multiple milestone payments.
• Downstream economic participation.

The split between design and development

Under the announced division of responsibility:

• XtalPi: Handle de novo design, meaning the creation of new molecular structures, and deliver novel small-molecule therapeutics against undisclosed targets.
• Laboratoires Pierre Fabre: Apply disease-biology, discovery, translational-research and clinical-development expertise to select and advance the most promising compounds, then oversee subsequent clinical and commercial development.

XtalPi’s integrated AI capabilities and robotics platform will sit at the front end of the partnered process. Its resulting molecules will move into Laboratoires Pierre Fabre’s selection work.

That structure gives Laboratoires Pierre Fabre continuity from the selection decision through the later development path. XtalPi’s defined role remains the design and delivery of the underlying molecules.

Francesco Hofmann, head of pharma research and development at Laboratoires Pierre Fabre, described XtalPi’s AI expertise as “a critical addition to our R&D Data and AI roadmap and to our discovery engine.”

What does this change for Laboratoires Pierre Fabre?

It adds an AI-enabled discovery component to Laboratoires Pierre Fabre’s R&D roadmap and strengthens the company’s drug-discovery capabilities, the companies said. In practice, XtalPi enters upstream, creating molecular designs that Laboratoires Pierre Fabre will assess with its disease-biology and translational-research expertise.

Laboratoires Pierre Fabre retains responsibility for choosing the most promising compounds and for subsequent clinical and commercial development. The deal therefore expands its discovery options without transferring those later development duties to XtalPi.

Why the research targets matter

The companies said the programs will focus on challenging targets that have historically resisted drug discovery. They associate those targets with significant unmet medical need and substantial opportunities for innovative drug discovery.

Oncology provides the stated base across multiple research programs. Dermatology and rare diseases are potential additions, creating several research settings in which XtalPi’s designs can be assessed through Laboratoires Pierre Fabre’s expertise.

The joint goal is to accelerate the identification of high-quality clinical candidates. The companies emphasize both quality and speed, with the intended output being compounds strong enough to become clinical candidates in areas where discovery has been difficult.

For XtalPi, the collaboration advances its effort to apply AI and robotics to de novo drug discovery. It also places the platform inside partnered therapeutic programs with a defined route into clinical and commercial development. For Laboratoires Pierre Fabre, the agreement adds AI-enabled discovery while keeping selection and downstream development with the company.

Where the value gets tested

The first test arrives at the handoff between molecular design and development. For historically hard-to-drug targets, XtalPi’s designed molecules must become compounds Laboratoires Pierre Fabre considers promising enough to advance. The broader test is whether they meet the companies’ goal of high-quality clinical candidates in areas with unmet medical need.

For practitioners tracking the agreement, the key signal is the conversion of designed molecules into candidates that clear Laboratoires Pierre Fabre’s filters. In the companies’ description, the multiple programs create several research settings for that assessment, with oncology as the stated base and dermatology and rare diseases as potential additions.

The next proof point is straightforward: XtalPi’s designed molecules must pass Laboratoires Pierre Fabre’s selection process and advance toward the companies’ goal of high-quality clinical candidates in therapeutic areas with significant unmet medical need.